It's easy it is to game almost any ranking system, not that I've tried to. As such. These are just what they are.
THIS BLOG IS ONLY A BLOG, NOT LEGAL ADVICE. IT IS IN PART AN ADVERTISEMENT FOR LEGAL SERVICES BY ME, LAWYER RONALD D. COLEMAN, BUT I AM NOT YOUR LAWYER. YOU ARE NOT MY CLIENT. JUST WALK BESIDE ME AND BE MY FRIEND.
The term of art maven is used to mean "wise guy" here and is not meant to suggest that I have certified or other "expertise" in any particular field of legal practice. But try me.
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Astrazeneca AB et al. v. Aurobindo Pharma Ltd. et al. 3:13-cv-07298; filed December 3, 2013 in the District Court of New Jersey • Plaintiffs: Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc. • Defendants: Aurobindo Pha […]
December 9, 2013 - Biotechnology/Chemical/Pharmaceutical (BCP) customer partnership meeting (U.S. Patent and Trademark Office) - 9:00 am to 2:45 pm (ET) December 9-10, 2013 - Patent Infringement Litigation Summit (Legal iQ (IQPC)) - San Francisco, CA December 10-11, 2013 - Advanced Forum on Patent Litigation*** (American Conference Institute) - New York, NY […]
The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on Monday, December 9, 2013. The agenda for the meeting is as follows: Morning Session • Meet and Greet (8:30 - 9:00 am ET) -- Wanda Walker, Jerry Lorengo, and James Wilson (Acting), Directors, TC1600 SPEs • Opening Remarks ( […]
Momentum Event Group will be holding its inaugural "IP Counsel Exchange for Biosimilar Applicants and Sponsors" January 23-24 in New York City. The effect of the recent Sandoz v. Amgen decision on biosimilar patent litigation strategy is expected to be...
This petition for review deals with one of those cases where emotions run high during the oral proceedings (OPs). The professional representative of the patent proprietor, whose patent had been revoked by Board 3.5.03 (case T 2198/10), had the very bad idea of using very strong language in the petition.In the course of the proceedings, the patent proprietor […]